F or all cancer sites combined, the majority of American Indian and Alaska Native (AI/AN) populations have exhibited rates lower than or similar to those of non-Hispanic white (NHW) populations or members of all racial groups combined. [1] [2] [3] [4] However, for cervical cancer and for preinvasive cervical lesions, prior investigations have found AI/AN women to have higher rates than other populations. 1, [5] [6] [7] [8] [9] Furthermore, the majority of data regarding cervical cancer mortality in AI/AN women published to date demonstrated substantially higher rates in comparison to NHW women. 5, 8, 10, 11 This discrepancy has been most dramatically demonstrated among AI/AN women in the Southwest compared with other populations in the Southwest, through data collected by the New Mexico Tumor Registry, a long-standing Surveillance, Epidemiology, and End Results (SEER) site that operates with a minimum of racial misclassification. 5, 6, 12 Although rates for invasive cervical cancer in AI/AN women in New Mexico and Alaska have been declining in recent years, 13, 14 rates for preinvasive lesions have remained high in some groups. 5, 9, [15] [16] [17] Despite studies from limited geographic regions, AI/AN women have often been excluded from national and state reporting on cervical cancer because of race misclassification in central cancer registries. [18] [19] [20] [21] The purpose of the current study was to improve our characterization of invasive cervical cancer incidence and stage at diagnosis in AI/AN women relative to NHW women, using techniques to minimize the effect of race misclassification in cancer surveillance data.
MATERIALS AND METHODS
Detailed descriptions of the data sources and methods used for this analysis are found in another article in this supplement. 22 
Cancer Cases
US state and regional population-based cancer registries collect information on new cancer diagnoses. 23 They participate in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC), the SEER Program of the National Cancer Institute (NCI), or both. 24 Primary cancer site and histology data are coded according to the International Classification of Diseases for Oncology (ICD-O) edition in use at the time of diagnosis and converted to the third edition. 25 For this study, cervical cancer incidence data generally refer to invasive cancers (ICD-O-3 C530-C539); lymphomas originating in the lymphatic tissue of the cervix, other histologies involving hematopoietic diseases, mesotheliomas, and Kaposi sarcomas were excluded (M9590-9989, 9050-9055, 9140). We did not examine in situ cervical tumors, which have not been reportable to NPCR and SEER since 1996. All cervical cancer data included in this study have been reviewed by cancer registrars, and meet the US Cancer Statistics standards 24 ; the states that met quality criteria and that are included in the analysis are listed in the footnotes of Table 1 .
Coding race for AI/AN cancer cases in this report combines information from 2 sources: 1) data linkages with the Indian Health Service (IHS) patient registration database, developed because the IHS provides medical services to AI/AN persons who are members of federally recognized tribes; and 2) the multiple race fields in central cancer registry records. 26 To reduce the misclassification of AI/AN race, all case records from each state were linked with the IHS patient registration database to identify AI/AN cases misclassified as another race. Linkages were conducted using LinkPlus, a probabilistic linkage software program developed by the CDC that was applied to key patient identifiers (social security number, first name, last name, middle initial, date of birth, and date of death). 27 Possible matches, requiring manual review, were examined independently by 2 reviewers, and when necessary, adjudicated by a third reviewer. The information from the linkages was then combined with the multiple race fields coded in cancer registry records. Further details regarding the linkage and coding rules for multiple races are described elsewhere in this supplement. 22 Contract Health Service Delivery Area (CHSDA) counties and IHS regions were geographic factors used to characterize further the burden of cancer incidence in the AI/AN population. CHSDA counties, in general, contain federally recognized tribal lands or are adjacent to tribal lands. The proportions of AI/AN persons in relation to total population are higher in CHSDA counties than in non-CHSDA counties, and CHSDA counties demonstrate less race misclassification for AI/ANs. 28 Data are presented for CHSDA counties and for all counties; however, because the information is believed to be more accurate for AI/AN persons living in CHSDA counties, the focus of the analyses is on AI/AN residing in CHSDA counties. The analysis of AI/AN data by IHS region (Alaska, Pacific Coast, Northern Plains, Southern Plains, Southwest, and East) conforms with known regional patterns of specific health outcomes and disease risk factors for AI/AN. 11, 29 A map depicting the IHS regions and indicating states and CHSDA counties included in the analysis is presented in Figure 
Population Estimates
Using population estimates from the Census Bureau and the CDC's National Center for Health Statistics, 32 the NCI makes additional refinements regarding race and county geographic codes; these estimates were used as denominators in this report.
22,33

Statistical Analyses
Two sets of statistics are provided for AI/AN and NHW women: 1) data from all counties in 46 states and the District of Columbia (referred to as 'All Counties'), and 2) data from counties designated as CHSDA. In addition, All Counties data and CHSDA counties data are provided for each IHS region. The results described in the text refer to persons who reside in CHSDA counties unless otherwise noted. Additional information concerning cases and population coverage is available elsewhere in this supplement. 22 For all AI/AN and NHW populations, cancer incidence rates were expressed per 100,000 persons and were age-adjusted by 19 age groups (<1 year, 1-4, 5-9, . . . , 80-84, and 851 years) to the 2000 US standard population. Percent distributions for stage of disease at diagnosis are also age-adjusted. For all analyses, exact counts were suppressed when the category of interest contained 5 cases. The age groups for the cervical cancer analysis (15-29, 30-49, 50-64 , and 651 years) were selected with consideration of screening recommendations and other age-related influences on screening and prevention, such as Medicare benefits for those aged 65 years.
Using the age-adjusted incidence rates, standardized rate ratios (RRs) were calculated for AI/AN women using NHW rates for comparison. Confidence intervals for age-adjusted rates and standardized RRs were calculated based on methods described by Tiwari et al 34 using SEER*Stat 6.3.6 statistical software. 35 
RESULTS
Our most important findings are summarized in Tables 1 through 3. Table 1 demonstrates regional variations in invasive cervical cancer incidence rates, per 100,000 population, for AI/AN women that are more striking than the variation among NHW women. For the period 1999 through 2004 for AI/AN women residing in CHSDA counties, invasive cervical cancer incidence rates ranged from 14.1 in the Southern Plains to 6.9 in the Pacific Coast region. The rate for AI/AN women in the Northern Plains was also elevated (12.5) in comparison with other regions. For all regions combined, the incidence rate was 9.4, which was significantly higher than the rate for NHW women (7.4; RR of 1.28). Rates for AI/AN females in All Counties were substantially lower than those in CHSDA counties and will not be presented for subsequent tables.
The age-specific rates for invasive cervical cancer changed most notably for AI/AN women from their 30s and 40s, remained elevated through 64 years of age, and were highest for women aged 65 years (Table 2 ). This trend was consistent for most geographic areas nationwide. The mean age at diagnosis for AI/AN women was 47.3 years versus 50.1 years for NHW women (data not shown). The differences in incidence rates for invasive cervical cancer between AI/AN women and NHW women in CHSDA counties increased with age. For AI/AN women aged 65 years, rates were 85% higher than for NHW women. Rates for AI/AN women were highest in the oldest age group, in contrast to NHW women, who demonstrated the highest rates among women ages 30 to 49 years. For those women ages 30 years to 49 years, Southern Plains AI/AN women had the highest rates for all the regions, but for AI/AN women in the oldest age group, Northern Plains women had the highest rates.
Stage of disease at diagnosis is shown in Table 3 for AI/AN and NHW women in CHSDA counties. Herein, we noted a lower rate and proportion of lesions diagnosed at the local stage (confined to the cervix) among AI/AN women compared with NHW women, and higher rates for regional and distant stage cervical cancer among AI/AN women compared with NHW women, for all regions combined. Although specific regions of the country demonstrated some variability with respect to stage at diagnosis, the majority of the findings were consistent with the All-Regions pattern and generally demonstrated lower rates and proportions of early invasive cancer for AI/AN women.
DISCUSSION
Our results demonstrated regional differences in incidence rates of invasive cervical cancer in AI/AN women, with women in the Northern and Southern Plains having the highest rates of the disease. Furthermore, the rates comparing AI/AN with NHW women were approximately 70% and 55% greater in the Northern and Southern Plains regions, respectively. Although rates of cervical cancer among AI/ AN women vary by region and remain overall higher than in NHW women, in New Mexico and Alaska (the only regions of the US with substantial AI/AN populations in which analyses examining long-term incidence trends have been possible), rates have decreased substantially since the 1970s. 5, 13, 14 Studies in non-AI/AN populations have demonstrated that >50% of incident cervical cancer cases can be attributed to no screening and another 10% to no recent screening. 36, 37 Rates of invasive cervical cancer in AI/AN women are currently lower than earlier published reports; the decrease in rates can be attributed, in part, to aggressive screening programs that have been put into place in numerous clinics that serve AI/AN women nationwide. The IHSinitiated cervical cancer screening in the 1960s and 1970s resulted in declining cervical cancer incidence and mortality rates in the 1980s and 1990s. 5, 13, 14 With the establishment of the CDC's National Breast and Cervical Cancer Early Detection Program (NBCCEDP), additional resources became available to increase screening in AI/AN women. 38 Programs in all 50 states and 14 tribes (Arctic Slope Native Association Limited, Barrow, Alaska; Cherokee Nation, Tahlequah, Oklahoma; Cheyenne River Sioux Tribe, Eagle Butte, South Dakota; Hopi Tribe, Kykotsmovi, Arizona; Kaw Nation of Oklahoma, Newkirk, Oklahoma; Mississippi Band of Choctaw Indians, Choctaw, Mississippi; Native American Rehabilitation Association of the Northwest, Portland, Oregon; Navajo Nation, Window Rock, Arizona; Poarch Band of Creek Indians, Atmore, Alabama; South East Alaska Regional Health Consortium, Sitka, Alaska; South Puget Intertribal Planning Agency, Shelton, Washington; Southcentral Foundation, Anchorage, Alaska; and Yukon-Kuskokwim Health Corporation, Bethel, Alaska) currently receive support from this program to build infrastructure and provide screening services. The prevalence of Papanicolaou (Pap) screening in all counties and all regions combined for the period 1999 through 2006 based on Behavioral Risk Factor Surveillance data as reported elsewhere in this supplement 39 remains slightly lower for AI/AN women than for NHW women (78% vs 84%, respectively). Regional prevalence estimates of Pap utilization only loosely reflect regional incidence rates; however, the observation that the Southern Plains region has the highest incidence rate of cervical cancer and the lowest attendance for Pap screening 39 indicates that screening prevalence influences regional patterns of cervical cancer incidence in AI/AN women.
During a site visit to the Navajo Reservation in 1989, the American College of Obstetricians and Gynecologists' Committee on American Indian Affairs identified access to colposcopy, a part of the standard diagnostic follow-up for abnormal Pap test results, as an important unmet need. In response, the CDC began supporting the IHS to conduct colposcopy training, annual training for primary care providers to increase the availability of this service and to reduce the time interval from abnormal screening results to definitive diagnosis. 40, 41 Since then, the IHS has increased the availability of colposcopy nationwide by training IHS and tribal providers. The IHS program provides basic colposcopy training with a didactic course followed by a hands-on preceptorship. In addition, annual review workshops and biennial colposcopy update courses enhance the skills of new and experienced colposcopists caring for AI/AN women. As of 2007, this training has reached 284 physicians and advanced practice clinicians (certified nurse midwives, nurse practitioners, and physician assistants) from 105 IHS, tribal, and urban Indian hospitals and clinics nationwide (unpublished data). Continued diligence in education, training, and prevention services is essential to further reduce the death rate from cervical cancer. Clinicians and public health practitioners, including those involved in the NBCCEDP, deserve much praise for their roles in lowering rates of cervical cancer, and the comparatively low rates among AI/AN women now should be viewed as a public health achievement of substantial magnitude. Despite the progress in reducing overall cervical cancer rates, the higher overall rates in AI/AN women and the unfavorable profile of local versus advanced stage of disease at diagnosis indicate a continued need for aggressive and comprehensive screening and timely follow-up of abnormal results. In addition to continued education and vigilance related to screening, AI/AN women should be made aware of the signs of cervical cancer (bleeding, especially after intercourse) and the critical importance of seeking immediate care if that clinical sign is apparent. Furthermore, it is critical to support screening programs with capacity to provide timely follow-up care for women with abnormal Pap smears.
Previous research in other populations has documented an increased risk of cervical cancer or of preinvasive cervical lesions among women of lower socioeconomic status. 42, 43 In 1 study among women in the Southwest, AI/AN women with less than a high school education and low annual income were found to be at an increased risk of developing cervical intraepithelial neoplasia (CIN). 16 In a similarly designed study of risk factors for CIN among New Mexico Hispanics and NHWs, Becker et al 44 also found strong risks associated with low economic status and education levels. Brinton and Fraumeni reported an inverse relation between socioeconomic indicators of income and education and risk of invasive cervical neoplasia for both black and white women. 45 For the period 2000 through 2006, poverty among the AI/AN population nationally was 3 times that of the NHW population, with the highest regional prevalence of poverty noted in AI/ANs in the Southwest. 4 Furthermore, AI/AN adults were less likely to have graduated from high school and were more likely to have less than a ninth grade education than NHW adults, with the Southwest and East AI/ AN populations experiencing the highest prevalence of not finishing high school. 4 Economic conditions in the Plains states are also very unfavorable for AI/AN people, compared with the NHW population.
Nonetheless, from an etiologic standpoint, poverty and low levels of education are not the direct cause of abnormal cervical epithelium, but only a correlate of other factors, the most of important of which is infection with oncogenic subtypes of human papillomavirus (HPV). Finally, cigarette smoking increases the risk for cervical neoplasia. 46 Because AI/AN women have a much higher prevalence of cigarette smoking, especially in the Plains region and Alaska, 39 addressing this important risk factor is critical to control a host of adverse health outcomes, including cervical cancer.
The data from the current study generally demonstrated higher age-specific cervical cancer rates for AI/AN women compared with NHW women, for most regions of the country and for most age categories that we examined. However, racial differences in rates were much less pronounced for the youngest age group of women. In some regions, for certain age groups, rates for NHW women exceeded rates for AI/AN women (see Table 3 ), although this observation is the exception and may reflect the instability of the AI/AN rates because of relatively small numbers of cases. The current study data do not allow us to identify those factors that explain the higher rates for NHW women than for AI/AN women in certain regions.
Our analysis indicated that AI/AN women are more commonly diagnosed with cervical cancer at a later stage than NHW women. Many factors influence the stage at which cervical cancer is diagnosed, and AI/AN women face several barriers to the early detection of cervical dysplasia and invasive cancer. Provider time pressures, health systems designed primarily for acute and episodic care, and an underfunded health system are potential barriers IHS and tribal providers may face. In addition, cultural reluctance to access Western medicine for nonacute health problems and transportation difficulties are factors commonly cited as barriers to cancer screening by AI/AN individuals. [47] [48] [49] [50] Although 2 HPV vaccines designed to prevent cervical neoplasia are being tested, only 1, the quadrivalent vaccine, is now licensed in the US and recommended for use among females ages 9 years to 26 years. In some parts of the country, health administrators are aggressively promoting vaccine uptake among AI/AN patients (unpublished data). The Vaccines for Children Program (VFC) is a federal entitlement program allowing private and public providers who participate in the VFC program to vaccinate eligible children with federally purchased vaccines as approved by the CDC's Advisory Committee on Immunization Practices. Children aged 19 years who are Medicaid eligible, uninsured, AI/AN (as defined by the Indian Health Services Act), are eligible to receive vaccine from providers through the VFC program. 51 We will not have adequate information to determine whether the vaccine will reduce cervical cancer rates for many years, in AI/AN (or other) populations, but the vaccine could have a more immediate impact on the incidence of abnormal cytology, the number of follow-up procedures, and cervical dysplasia.
As HPV vaccine development expands to include other HPV types that cause cervical neoplasia, greater reductions in preinvasive lesions can be expected. Monitoring the HPV types infecting AI/AN women will help determine whether vaccination or newer technologies in screening are having an impact. In collaboration with the New Mexico Department of Health, investigators in New Mexico have developed a statewide Pap smear registry. Linkage of this registry to the New Mexico statewide immunization information system and, eventually, to the New Mexico Tumor Registry will be important to determining the efficacy, effectiveness, and safety of the HPV vaccine. The support and partnership of tribes and participation of AI/AN women will be crucial to evaluate the cervical cancer control efforts in that state (unpublished data). Researchers in Alaska plan an array of activities focusing on implementing and monitoring the HPV vaccine in AI/AN women. These include educating the public regarding the vaccine, monitoring vaccination coverage, measuring the impact on rates of dysplasia and cancer, evaluating antibody duration, studying the HPV types found in women undergoing colposcopy, and determining the economic impact of the vaccine (unpublished data).
There are several important limitations to our analyses to consider when interpreting these results. These include incidence rates based on small case numbers, particularly when data are presented by region and age group. Although data on screening prevalence for AI/AN women reported by Steele et al are presented elsewhere in this supplement, 39 we do not know the patterns of adequate follow-up or the distribution of oncogenic HPV subtypes that may determine differences in cervical cancer between AI/ AN and NHW women. Furthermore, we do not know the proportion of AI/AN women or NHW women who have undergone hysterectomies and are no longer at risk for cervical disease.
Previous studies have shown that many AI/AN were misclassified as another race in cancer registry data and that the extent of misclassification varied by registry. [18] [19] [20] [21] Although linkages between cancer registry data and the IHS patient registration database improve the race classification for AI/AN cases, AI/AN persons who are not members of the federally recognized tribes, live primarily in urban settings, live long distances from IHS facilities, live in counties other than those designated as CHSDA, or are not eligible for IHS services are under-represented in the IHS database. Additional details regarding the misclassification of AI/AN race are available elsewhere in this supplement. 16 Because we restricted the majority of the analyses to CHSDA counties, in which only 56% of AI/AN live and which tend to be located in more rural areas and Western states (Fig. 1) , the results should not be generalized to all AI/AN (or NHW) women in the US. In addition, the percentage of the AI/AN population residing in CHSDA counties varies greatly among the 6 IHS regions. The percentage is particularly low in the East region (15%).
In summary, the results of the current study indicate a much improved picture of reduced incidence of invasive cervical cancer in AI/AN women. Nonetheless, the rates in the Northern and Southern Plains regions noted during the study period are higher than the rates for AI/AN women in other regions or for NHW women; furthermore, AI/AN women in general had proportionally more late-stage diagnoses. For these reasons, additional steps must be taken to decrease further the rates in AI/AN women. Because smoking is an independent risk factor for cervical cancer, tobacco use prevention efforts among AI/AN populations is essential, in addition to increasing the uptake of screening among AI/AN women. Although the HPV vaccine may have an effect in rate reduction in future generations, aggressive screening programs must remain in place. Vigilance concerning screening on the part of clinicians and their AI/AN patients clearly remains an important approach to cervical cancer control. For more information about cervical cancer, please visit www.cdc.gov/cancer/gynecologic.
